Review





Similar Products

mes sa cells  (ATCC)
96
ATCC mes sa cells
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Mes Sa Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mes sa cells/product/ATCC
Average 96 stars, based on 1 article reviews
mes sa cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
immune cell isolation te671 rhabdomyosarcoma cells  (ATCC)
96
ATCC immune cell isolation te671 rhabdomyosarcoma cells
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Immune Cell Isolation Te671 Rhabdomyosarcoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immune cell isolation te671 rhabdomyosarcoma cells/product/ATCC
Average 96 stars, based on 1 article reviews
immune cell isolation te671 rhabdomyosarcoma cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
mes sa dx5 cells  (ATCC)
96
ATCC mes sa dx5 cells
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Mes Sa Dx5 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mes sa dx5 cells/product/ATCC
Average 96 stars, based on 1 article reviews
mes sa dx5 cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
human glioblastoma cells  (ATCC)
96
ATCC human glioblastoma cells
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Human Glioblastoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glioblastoma cells/product/ATCC
Average 96 stars, based on 1 article reviews
human glioblastoma cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cho cells  (ATCC)
96
ATCC cho cells
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Cho Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cho cells/product/ATCC
Average 96 stars, based on 1 article reviews
cho cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
uterine sarcoma cell lines mes sa  (ATCC)
96
ATCC uterine sarcoma cell lines mes sa
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Uterine Sarcoma Cell Lines Mes Sa, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uterine sarcoma cell lines mes sa/product/ATCC
Average 96 stars, based on 1 article reviews
uterine sarcoma cell lines mes sa - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
mes sa uterine sarcoma cells  (ATCC)
96
ATCC mes sa uterine sarcoma cells
a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous <t>(s.c.)</t> <t>MES-SA</t> cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.
Mes Sa Uterine Sarcoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mes sa uterine sarcoma cells/product/ATCC
Average 96 stars, based on 1 article reviews
mes sa uterine sarcoma cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

Image Search Results


a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous (s.c.) MES-SA cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.

Journal: Nature

Article Title: In vivo site-specific engineering to reprogram T cells

doi: 10.1038/s41586-026-10235-x

Figure Lengend Snippet: a , Tumour challenge schematic for multiple myeloma. NSG MHC-I/II double-KO mice received i.v. OPM2 cells (1 × 10 6 ), followed 5 days later by human PBMCs (1 × 10 7 ). Then, 5 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse; Cas9–sgTRAC) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding a BCMA-1XX-CAR-P2A-EGFRt. The tumour burden was monitored using BLI. At day 35 after EDV/AAV treatment, mice were rechallenged i.v. with OPM2 cells (5 × 10 6 ). b , BLI measurements in mice injected with OPM2 alone ( n = 5), OPM2 + PBMC ( n = 8) or OPM2 + PBMC + EDV/AAV ( n = 8). Rechallenge was performed in four EDV/AAV-treated mice that controlled tumour growth by day 35 and in five age-matched control mice. BLI values represent the mean of dorsal and ventral signals (photons per s per cm 2 ). c , Tumour challenge schematic for solid tumours. NSG MHC-I/II double-KO mice received subcutaneous (s.c.) MES-SA cells (4 × 10 6 ), followed 4 days later by human PBMCs (1 × 10 7 ). Then, 3 days after PBMC transfer, mice received PBS or anti-CD3-EDV (5 × 10 11 sgRNAs per mouse) plus AAV-hT7 (1 × 10 12 vg per mouse), delivering a TRAC HDRT encoding an anti-B7H3-CD28ζ-1XX-CAR-P2A-EGFRt. The tumour burden was assessed by calliper measurements. d , Kaplan–Meier survival analysis of mice bearing MES-SA tumours; MES-SA only ( n = 4), MES-SA + PBMC ( n = 5) or MES-SA + PBMC + EDV/AAV (anti-B7H3–CD28ζ−1XX TRAC CAR; n = 6). e , Tumour growth measurements from the mice in d . CR, complete response. Images in a and c were adapted from Servier Medical Art ( https://smart.servier.com/ ), under a CC BY 4.0 licence.

Article Snippet: MES-SA cells (ATCC, CRL-1976) were cultured in McCoy’s 5a modified medium (Gibco, 16600082) supplemented with 10% FBS and penicillin–streptomycin.

Techniques: Injection, Control

a , Dorsal images from mice described in Fig. . BLI is displayed as radiance (p/sec/cm 2 /sr). Days are indicated from time of PBS or EDV/AAV treatment. Day 11, 14, 21, 28 ans 35 are shown with and without mice that are saturating the signal. b , Total body weight from mice in Fig. . c , Experimental conditions from Fig. were repeated with an additional PBMC donor. Kaplan-Meier survival analysis in mice injected with MES-SA only (n = 4), MES-SA and PBMC (n = 5), MES-SA, PBMC and EDV/AAV targeting a aB7H3-CD28z-1XX (n = 6) CAR to TRAC . d , Tumour measurements in mice injected with MES-SA only (n = 4), MES-SA and PBMC (n = 5), MES-SA, PBMC and EDV/AAV targeting a aB7H3-CD28z-1XX (n = 8) CAR to TRAC . e , Total body weight from mice in c , d .

Journal: Nature

Article Title: In vivo site-specific engineering to reprogram T cells

doi: 10.1038/s41586-026-10235-x

Figure Lengend Snippet: a , Dorsal images from mice described in Fig. . BLI is displayed as radiance (p/sec/cm 2 /sr). Days are indicated from time of PBS or EDV/AAV treatment. Day 11, 14, 21, 28 ans 35 are shown with and without mice that are saturating the signal. b , Total body weight from mice in Fig. . c , Experimental conditions from Fig. were repeated with an additional PBMC donor. Kaplan-Meier survival analysis in mice injected with MES-SA only (n = 4), MES-SA and PBMC (n = 5), MES-SA, PBMC and EDV/AAV targeting a aB7H3-CD28z-1XX (n = 6) CAR to TRAC . d , Tumour measurements in mice injected with MES-SA only (n = 4), MES-SA and PBMC (n = 5), MES-SA, PBMC and EDV/AAV targeting a aB7H3-CD28z-1XX (n = 8) CAR to TRAC . e , Total body weight from mice in c , d .

Article Snippet: MES-SA cells (ATCC, CRL-1976) were cultured in McCoy’s 5a modified medium (Gibco, 16600082) supplemented with 10% FBS and penicillin–streptomycin.

Techniques: Injection